Acceleron Buoyed By Sotatercept’s Promise In PAH
Pipeline Turnaround After 2019 Disappointments
Top-line Phase II results from the PULSAR study suggest Acceleron’s sotatercept is effective as add-on treatment for patients with PAH, and could be a new class of therapy for a still difficult-to-control condition.
